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Abstract:  Isoflavones, phytoestrogens in soy beans with estrogen-like properties, have 
been examined for their cancer protective effects. Mammographic density is a strong 
predictor of breast cancer. This review summarizes studies that have examined the 
association between isoflavones and breast density. Observational investigations in Hawaii 
and Singapore suggest slightly lower breast density among women of Asian descent with 
regular soy intake, but two larger studies from Japan and Singapore did not observe a 
protective effect. The findings from seven randomized trials with primarily Caucasian 
women indicate that soy or isoflavones do not modify mammographic density. Soy foods 
and isoflavone supplements within a nutritional range do not appear to modify breast 
cancer risk as assessed by mammographic density.  
Keywords:  breast cancer risk; mammographic density; soy foods; isoflavones; Asian 
ethnicity; epidemiology; randomized trials 
 
1. Introduction  
The low breast cancer rates in Japan as compared to Western countries and epidemiologic   
evidence [1,2] offer support for the hypothesis that soy intake protects against breast cancer. 
Investigations among women with Japanese and Chinese ancestry suggest that beneficial effects are 
more likely to be present in women who consumed soy during childhood and adolescence [2-4]. This 
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review summarizes investigations that have examined the association between isoflavones and 
mammographic density as a marker for breast cancer risk. In addition, we present background 
information on the potential mechanisms of action for isoflavones and on the concept of 
mammographic density as a surrogate outcome for breast cancer and its relation to steroid hormones. 
2. Background  
2.1. Isoflavones  
 
Soy and soy derived foods are by far the richest source of isoflavones (genistein, daidzein, and 
glycitein) in the human diet [5]. Isoflavones are considered phytoestrogens because of their estrogen-
like structure and properties [6]. Daily isoflavone intake has been estimated as 25–50 mg in Asian 
countries, where traditional soy foods, such as tofu and soy milk, are commonly consumed [7] but is 
less than 1 mg in most Western countries [1,2]. Red clover is another source of isoflavones; biochanin 
A and formononetin yield genistein and daidzein after conversion in the intestinal tract [8]. Due to 
their estrogen-like structure, isoflavones have the ability to bind to estrogen receptors (ER). Their 
preference for ERβ over ERα has been proposed as the basis for their protective action against   
cancer [9]. ERα expression appears to be positively correlated with cell proliferation in mammary 
tumors in soy-treated rats [10], whereas ERβ transfection studies have demonstrated diminished 
proliferation and invasion in cell lines [11] suggesting that the relative proportion of the two receptors 
is important [12]. The frequency of ER expression may also contribute to the lower breast cancer risk 
among Japanese as compared to Caucasian women [13]. In the absence of steroidal estrogens, 
isoflavones appear to have weak estrogenic effects, whereas in the presence of steroidal estrogen, they 
exert an antagonistic effect through a competitive, ER-mediated mechanism [14]. Thus, isoflavones 
may prevent the proliferative effect of sex steroids on breast tissue, thereby lowering breast   
cancer risk.  
If isoflavones act on breast cancer risk through an antiestrogenic mechanism, it is possible that 
isoflavone supplementation in premenopausal women with high circulating estrogen levels is not 
sufficient to influence breast cancer risk. However, in postmenopausal women with low circulating 
estrogen levels primarily derived through conversion from androgens in adipose tissue, isoflavones 
from foods or supplements may be more likely to exert an estrogen-like action on the breast raising 
some concern about adverse effects [15]. In addition, several other mechanisms of action have been 
proposed as mediators between soy intake and breast cancer risk. Isoflavones may lower estrogen 
levels through stimulation or upregulation of sex hormone binding globulin in the liver [16], 
downregulation of enzymes involved in estrogen biosynthesis such as aromatase that converts 
androgens to estrogens [17], inhibition of 17,3-hydroxysteroid-oxido reductase that converts estrone to 
the more potent estradiol [18], and effects on the intestinal flora that may decrease reabsorption of 
estradiol [19,20]. In addition, evidence has emerged that soy may protect against breast cancer through 
non-estrogenic pathways such as antioxidative, anti-inflammatory effects, or inhibition of 
topoisomerase or tyrosine kinase [21,22]. Finally, the weak estrogenic effects of isoflavones early in 
life [23] may achieve or accelerate differentiation of breast tissue structures similar to an early 
pregnancy and, thereby, make the tissue less susceptible to carcinogens [24,25].  Nutrients 2010, 2                                       
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2.2. Mammographic Density and Breast Cancer Risk 
Mammographic density, one of the strongest breast cancer risk factors, describes the radiographic 
appearance of the female breast [26]. Fat, which is radiolucent, appears dark on mammograms. 
Epithelial and stromal tissues, on the other hand, appear white or radiodense and are collectively 
described as mammographic density. Women in the highest density category have a 4-6 fold higher 
breast cancer risk than those with very low densities [26]. Qualitative and quantitative methods have 
been used for density assessment on digitized or digital mammographic images. The first density 
assessment method was presented by Wolfe [27]. This qualitative approach classified the appearance 
of breast images into four categories and was later expanded to five classes by Tabar [28]. Later, visual 
estimation techniques provided quantitative results as a continuous outcome [29,30]. Computer-based 
methods using scanned mammographic images became widely used in the 1990s, also measure density 
on a continuous scale, and simplified the assessment of large numbers of films [31,32]. The most 
commonly used program (Cumulus) was developed in Toronto (Canada) [31,33]. When the different 
assessments methods are compared, they all describe the associations with well known breast cancer 
risk factors but the quantitative methods appear to capture more information than the qualitative 
methods [34]. Several volumetric approaches have been developed, although not commonly used yet, 
and have the goal to capture three- instead of two-dimensional images [35,36]. 
2.3. Steroid Hormones and Mammographic Density 
Hormone replacement therapy (HRT), in particular containing progestin, has been shown to 
increase mammographic densities [37]. As observed in several trials, breast density increased between 
3–5% in women taking estrogen/progestin combination therapy over at least one year, while no change 
was observed for the placebo and the estrogen only groups [38,39]. Such effects were expected based 
on the epidemiology of breast cancer and the relation of ovarian hormone levels to breast cell 
proliferation [40] and were confirmed by the Women's Health Initiative showing that combined 
estrogen-progestogen therapy significantly increases the risk of breast cancer [41]. A dramatic 
reduction of mammographic density was also observed in trials with a gonadotropin-releasing 
hormone agonist [42] and with tamoxifen [43] but not raloxifene [44]. Although these investigations 
support the use of breast density as a marker for breast cancer risk [40], it remains unclear, if the 
mammographic changes are causally linked to the higher breast cancer risk or if two separate pathways 
are involved [37,45].  
In comparison to HRT, the relation between mammographic density and endogenous sex steroids is 
less clear [45]. Whereas one cross-sectional investigation observed a significant association with 
estrogens [46], other reports did not [47-49]. Adjustment for body mass index (BMI) generally 
weakened the association but residual confounding for adiposity cannot be excluded [45]. It appears 
likely that mammographic density and circulating sex steroids are strongly and independently 
associated with breast cancer risk and that breast density does not mediate the effect of the endogenous 
hormones [48]. Similar to HRT, circulating progesterone may influence breast density more than 
estrogens. Among premenopausal women, progesterone showed a stronger association with 
mammographic density than estrogen [50].  Nutrients 2010, 2                                       
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3. Results  
Our search for studies on isoflavones and breast density identified six reports (Table 1) from five 
cross-sectional investigations [51-56], one longitudinal analysis [57], and eight publications from 
seven randomized trials (Table 2). We are summarizing findings for observational studies and 
randomized trials separately. A final section reviews publications that have examined equol-producing 
status and breast density. With one exception [52], all observational studies included women of Asian 
ancestry. On the other hand, all, but two interventions from Hawaii that included Japanese American 
women [58,59], were conducted in Caucasian populations who did not regularly consume foods with 
high isoflavone content. 
3.1. Observational Studies 
The cross-sectional studies (Table 1) and the longitudinal investigation examined the association 
between soy intake, as assessed by food frequency questionnaires, and breast density among healthy 
pre-and postmenopausal women [51-57]. A study in Hawaii detected a weak positive association 
between soy intake and percent mammographic densities [51]. While average breast area and the non-
dense area were approximately 25% smaller among women in the highest soy intake category 
compared with women in the lowest category, percent densities were 11% greater with higher soy 
intake. The dense areas appeared to be slightly smaller with increasing soy intake but the trend test 
was not significant. After stratification by ethnicity, the findings indicated non-significant differences 
by ethnicity. Whereas the relation was inverse, although not statistically significant, among Chinese 
and Japanese women, Caucasians with a higher soy intake had slightly higher mammographic 
densities. A small German study with a very low mean isoflavone intake (around 0.1 mg per day) 
reported a non-significantly higher isoflavone intake among pre- and postmenopausal women with 
non-dense breasts [52]. When breast density among 601 Japanese women was evaluated in relation to 
dietary soy isoflavones, no significant associations of isoflavones with percent density in pre- and 
postmenopausal women were detected [55]. In fact, breast density was non-significantly higher for 
women in the highest quartile, similar as for Caucasians in the Hawaii study [51]. The Japanese study 
used an automated mammographic mass detection method different from the approach applied in the 
other cross-sectional reports [55]. 
Two reports from the same study population in Singapore indicated possible beneficial effects of 
soy on breast density [53,54]. Dietary and other lifestyle profiles were compared between subjects 
classified as displaying high risk and low risk parenchymal patterns [53]. After adjustment for energy 
intake and other potential confounders, dietary soy protein intake was inversely related to the risk of 
high-risk parenchymal pattern; an estimated risk of 0.41 was observed when comparing extreme 
quartiles [53]. When a quantitative method of density assessment was applied to the same 
mammographic images, higher soy intake was associated with 4–5% lower percent densities [54]. A 
larger investigation of 3,315 Chinese women, also in Singapore, examined the combined effect of soy 
foods and green tea on breast density [56]. While the difference between the highest quartile and the 
lowest three quartiles combined was less than 2%, it was statistically significant in post- but not in 
premenopausal women. After adjustment for green tea intake, the association between soy and density 
was no longer significant indicating a stronger effect of green tea than soy on breast density [56].  Nutrients 2010, 2                                       
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Table 1. Cross-sectional studies on soy/isoflavones and mammographic densities. 
Author, Year 
N  
Status  
Isoflavone 
intake (mg) 
Assessment 
method
3 
Results for lowest and highest intake 
categories 
Maskarinec, 
2001 [51] 
514  
Pre & post 
Asians 8
1 Computer-
assisted 
Asians  38.2% and 34.5%; p = 0.31 
Whites 4
1  Whites  26.7% and 30.7%; p = 0.06 
Nagel, 2005  
[52] 
54  
Pre & post 
0.1 Wolfe  categories 
0.01 vs. 0.19 mg isoflavones in women 
with dense vs. non-dense breast; p = 0.26 
Nagata, 2005 
[55] 
601  
Pre & post 
Pre 42 
Automated 
Pre  30.2% and 37.8%; p = 0.28 
Post  75  Post  9.7% and 13.1%; p = 0.33 
Jakes, 2002  
[53]
2 
406  
Pre & post 
14 Tabar  categories 
Odds ratio of 1 and 0.44 to have dense 
breasts; p = 0.07 
Ursin, 2006  
[54]
2 
380  
Pre & post 
15 
Computer-
assisted 
26.1% and 21.2%; p = 0.03 
Wu, 2008 
[56] 
3,315 
Pre & post 
Pre 17  Computer-
assisted 
25.7% and 26.3%; p = 0.28 
Post 18 
Notes: 
1Estimated isoflavones in 38 and 22 g soy foods; 
2 Same study population;  
3All methods are quantitative except for Tabar and Wolfe categories 
 
Despite three suggestive reports [51,53,54], the negative results in the two larger cross-sectional 
investigations [55,56] indicate that the effect of regular soy intake on mammographic density, if it 
exists, is weak. Additional observational evidence comes from a nested case-control study conducted 
in Hawaii [57]. Early life soy intake as assessed by a lifetime soy questionnaire was weakly related to 
lower percent densities, while soy consumption during adulthood predicted significantly higher 
densities. The rate of change in breast density over time was not significantly affected by soy intake 
although women who consumed soy as adults appeared to experience a faster decline in density than 
women who consumed soy as early in life. 
3.2. Randomized Trials 
Of the eight reports describing seven randomized trials (Table 2), hormonal outcomes were the 
primary endpoints for three studies among premenopausal women [58-60], bone density for two trials 
in postmenopausal women [61,62], and a combination of health effects to assess safety of isoflavones 
for the two other interventions [59,63]. The hypothesis for clinical trials with the goal to examine 
breast density was that treatment with soy foods or isoflavones would decrease mammographic density 
as a marker of breast cancer risk. Of the seven randomized trials, two included only premenopausal 
women [58,59], three only postmenopausal subjects [61-63], and two pre- and postmenopausal   
women [60,64]. Soy foods, i.e., tofu, soy milk, soy nuts, and soy bars, were used in one [59], soy 
protein powder in one [63], soy-based isoflavone supplements in two [58,62], a genistein only 
supplement in one [61], and isoflavone tablets from red clover, primarily biochanin A and 
formononetin, in two interventions [60,64]. The duration of the trials ranged between 1-3 years, while 
the sample sizes varied from 30–401 participants. All interventions randomized healthy women, 
although at high breast cancer risk in one trial [64] and with high breast density in another one [60].  Nutrients 2010, 2                                       
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Table 2. Randomized trials with soy/isoflavones and breast density as outcome. 
Author 
Year 
N 
Status 
Treatment 
Iso dose 
(mg)
Duration 
(years)
Assessment 
method
4
Change in density (%)
Controls Intervention
Maskarinec 
2003 [58] 
30  
Pre 
Isoflavone 
supplement 
100 1 
Computer-
assisted
0.4 2.5 
Maskarinec  
2004 [59] 
213  
Pre 
Soy foods  50  2 
Computer-
assisted
-4.1 -2.8 
Powles  
2008 [64] 
401  
Pre & post 
Red clover 
supplement 
40 3 
Visual 
estimation
Pre -3.0  Pre  -6.6 
Post -8.0  Post  -6.9 
Verheus  
2008 [63] 
126  
Post 
Soy powder  99  1 
Computer-
assisted
-4.6 -2.5 
Marini 
2008 [61] 
138  
Post 
Genistein 
supplement 
54 3 
Wolfe 
categories
13.4
1 22.5
1 
Computer-
assisted
-0.4
2 -0.4
2 
Atkinson 
2004 [60]
3 
177  
Pre & post 
Red clover 
supplement 
45 1 
Visual 
estimation
-3.9 -3.2 
Kataoka 
2008 [65]
3 
 
177  
Pre & post 
 
Red clover 
supplement 
45 1 
Computer-
assisted
-0.5 -2.1 
Volumetric 0.8  0.3 
Maskarinec 
2009 [62] 
358  
Post 
Isoflavone 
supplement 
80 & 120  2 
Computer-
assisted 
-1.4/y 
80 mg  -1.6/y 
120 mg  -1.3/y 
Notes: 
1% improved category; 
2Arbitrary units, not percent density; 
3Same study population; 
4All methods are quantitative except for Wolfe 
categories 
 
In most studies, the mammograms had been obtained as part of regular medical care; the subjects 
were not exposed to additional radiation as part of the interventions. Therefore, due to current 
screening recommendations, women under 40 years could not be enrolled into the interventions. All 
trials except the soy-food based trial [59] were blinded and administered a placebo pill [58,60-62,64] 
or a milk-based powder [63] to subjects in the control group. In comparison to regular soy intake in 
Asian countries [7], the administered doses were substantially higher (80–120 mg) in three   
trials [58,62,63], while they were in the high nutritional range in the others [59-61,64]. Compliance 
was addressed by different methods in each trial and appeared satisfactory; overall drop-out rates were 
within the acceptable range. No major adverse effects were reported by any of the studies. The most 
recent trial was the multicenter Osteoporosis Prevention Using Soy (OPUS) study with a primary 
endpoint of bone density [62]. In a double-blinded and placebo-controlled design, two relatively high 
doses of 80 or 120 mg/d of isoflavones were administered for two years.  
All but three reports [60,61,64] used the same computer-assisted Cumulus method [31]. One 
investigation used both the Wolfe scale and a digitized quantification and detected no significant 
change with either method [61]. Another report compared the outcomes using three different 
assessment methods [65]. Re-examining the same mammograms as in the earlier report with Wolfe 
patterns [60], the investigators applied Cumulus and the volumetric standard mammogram form (SMF) 
method. Whereas no significant treatment effect was observed with the visual estimation and the SMF Nutrients 2010, 2                                       
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method, the intervention group showed somewhat greater reduction of percent density by Cumulus in 
comparison to controls (P = 0.04) but the difference was small (−2.1 vs. −0.5%) and was attenuated 
after adjustment for baseline percent density (P = 0.06). The OPUS trial had the challenge that some of 
the mammograms were digital, whereas the majority were regular film mammograms [62]. 
Fortunately, 83% of women received the same type of mammography throughout the study.  
In the 2-year nutritional trial, the effects of lifetime soy intake on mammographic density were also 
explored [59]. Soy intake since age 20 as measured by the lifetime soy questionnaire was negatively 
associated with annual change in percent density (P = 0.007). Women who reported at least one 
serving per week during adulthood experienced a greater decline in densities than women with lower 
intakes indicating that soy consumption throughout life may be associated with breast density, 
although this could be confounded by BMI and other lifestyle factors associated with high lifetime  
soy consumption. 
The eight reports, including the three high-dose trials, were in agreement that isoflavone or soy 
treatment did not result in statistically significant changes in mammographic densities when compared 
to the control arm [58-65]. However, with one exception [58], breast density decreased during the 
duration of the trial due to aging of the breast tissue as observed in longitudinal mammographic 
density studies [57,66]. For example, in the OPUS study mean percent density decreased by 1.6% per 
year across groups [62] and in the soy food trial annual declines of 1.2% and 1.9% were observed 
among intervention and control subjects [59]. 
3.3. Equol-Producer Status and Breast Density 
Soy consumption may have a stronger association with mammographic density in subjects who are 
able to metabolize the isoflavone daidzein to equol than those who cannot [67]. Several mechanisms of 
action have been proposed [68]. Equol may bind to ER with greater affinity than other isoflavonoids, 
the equol producing phenotype may be associated with other factors influencing breast density, or 
differences in intestinal bacterial populations may result in different reproductive hormone metabolite 
profiles and circulating hormone concentrations. Three studies assessed equol excretor status after a 
challenge with soy protein. The equol producers among a group of sedentary postmenopausal women 
in Seattle were found to have lower mammographic densities than the non-producers [68]. These 
results suggest that particular intestinal bacterial profiles that facilitate isoflavone metabolism may be 
associated with lower postmenopausal mammographic density. However, two other studies that 
stratified by equol excretor status did not detect any differences in breast density [63,69]. In a Dutch 
trial, equol producer status was assessed at the end of the trial using a 3-day soy challenge but the 
results were not affected by equol-producer status [63]. No significant independent associations of 
equol status or soy intake with percent density although a significant interaction between these factors 
was observed in another cross-sectional soy-challenge investigation [69]. 
4. Discussion and Conclusions  
Although cross-sectional investigations in Hawaii and Singapore suggest slightly lower breast 
density among women of Asian descent with regular soy intake [51,53,54], the two larger studies with 
Japanese and Chinese women did not observe any conclusive evidence for a protective effect [55,56]. Nutrients 2010, 2                                       
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With great consistency, the randomized trials indicate that soy or isoflavones do not modify 
mammographic densities among adult pre- and postmenopausal Caucasian women. Whereas the 
relatively short durations and the limited sample sizes may have been responsible for a lack of an 
effect on breast density in the trials presented here, it appears probable that isoflavones do not 
influence breast density in adult women who grew up in Western countries and consumed few 
isoflavones in their regular diet. A lack of an effect on mammographic density would not rule out a 
protective effect of isoflavones against breast cancer as indicated by case-control studies [1,2]. A 
modification in breast cancer risk through an intervention may not necessarily be reflected in breast 
density. Soy isoflavones may affect breast cancer through a different pathway than mammographic 
densities in the same way as proposed for endogenous steroid hormones [70,71] and postmenopausal 
obesity [72].  
The body of literature discussed here has a number of limitations. Nearly every trial reviewed here 
administered a different isoflavone containing product (Table 2) or even used only one aglycone 
isoflavone [61]. Non-fermented soy foods typically contain glucosides that are hydrolyzed to 
aglycones by intestinal bacteria and isoflavone aglycones may be absorbed faster and in greater 
amounts than glucosides [73]. The use of red clover as a source of isoflavones may have also affected 
the results given that biochanin A and formononetin are structurally different from soy   
isoflavones [8,60,64]. As shown for LDL cholesterol reduction, soy protein may be more effective 
than isoflavone supplements [74]. Despite the advantages of soy foods in that they replicate soy 
exposure in Asian countries, the one study using soy foods warrants cautious interpretation due to the 
lack of blinding [59]. The relatively high isoflavone doses used among women with low previous 
exposure may not be comparable to Asian soy exposures since early childhood [62,63]. Unfortunately, 
no data on the effects of soy in women under 40 years are currently available because the risk of 
radiation would outweigh the benefits of mammography. Therefore, it has not been possible to 
examine the hypothesis that soy exposure early in life reduces breast cancer risk to a greater degree 
than during adulthood [3,4].  
Methodological problems in density assessment raise some questions about the validity of the 
findings. As shown in a comparative report [65], there was a suggestion of a greater reduction of 
percent density in the isoflavone group than controls, but only when breast density was measured by 
Cumulus. Thus, it is possible that slightly different conclusions could be drawn by using different 
methods to assess breast density. As in all cross-sectional studies, confounding by other nutritional or 
lifestyle factors, e.g., fruit and vegetable intake, BMI, or physical activity, may have biased the results.  
On the positive side, the lack of an isoflavone treatment effect on breast density offers some 
reassurance to those who are concerned about the possible risks of soy foods [15]. Concerns were 
raised that the estrogen-like effects of isoflavones may induce breast cell proliferation [75,76]. The 
evidence from the randomized trials reviewed here indicates that consuming soy foods within a 
nutritional range does not increase breast density as reported for HRT [37] and it remains possible that 
long-term soy exposure may offer some protection against breast cancer [53,54,57]. This idea is 
supported by a recent report from China that observed a lower risk of breast cancer death and 
recurrence among women with higher soy consumption [77]. Despite methodological challenges, we 
need to understand better in the future how soy affects breast cancer risk earlier in life. As shown in 
several studies among Asian women, soy exposure during adolescence may play a more important role Nutrients 2010, 2                                       
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in breast cancer prevention than during adulthood [3,4]. Novel breast imaging approaches, such as 
MRI [78], ultrasound [79], and DXA [80], will be needed to understand nutritional influences on 
breast density in adolescents and young women. 
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